citalopram has been researched along with Cardiovascular Stroke in 14 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Excerpt | Relevance | Reference |
---|---|---|
"To investigate the effect on long-term major adverse cardiac events (MACE) of escitalopram treatment of depression in patients with recent ACS." | 9.27 | Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JH; Kim, JM; Kim, JW; Kim, MC; Kim, SW; Lee, HJ; Lee, YS; Shin, IS; Stewart, R; Yoon, JS, 2018) |
"TALOS is an investigator-initiated, national multicenter randomized- and placebo-controlled, double-blind trial testing citalopram in acute ischemic stroke." | 9.20 | TALOS: a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke. ( Andersen, G; Grove, EL; Johnsen, SP; Kraglund, KL; Mortensen, JK, 2015) |
"To investigate the effect on long-term major adverse cardiac events (MACE) of escitalopram treatment of depression in patients with recent ACS." | 5.27 | Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JH; Kim, JM; Kim, JW; Kim, MC; Kim, SW; Lee, HJ; Lee, YS; Shin, IS; Stewart, R; Yoon, JS, 2018) |
"TALOS is an investigator-initiated, national multicenter randomized- and placebo-controlled, double-blind trial testing citalopram in acute ischemic stroke." | 5.20 | TALOS: a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke. ( Andersen, G; Grove, EL; Johnsen, SP; Kraglund, KL; Mortensen, JK, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (35.71) | 29.6817 |
2010's | 9 (64.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kim, JM | 1 |
Stewart, R | 1 |
Lee, YS | 1 |
Lee, HJ | 1 |
Kim, MC | 1 |
Kim, JW | 1 |
Kang, HJ | 1 |
Bae, KY | 1 |
Kim, SW | 1 |
Shin, IS | 1 |
Hong, YJ | 1 |
Kim, JH | 1 |
Ahn, Y | 1 |
Jeong, MH | 1 |
Yoon, JS | 1 |
Kraglund, KL | 2 |
Mortensen, JK | 2 |
Damsbo, AG | 1 |
Modrau, B | 1 |
Simonsen, SA | 1 |
Iversen, HK | 1 |
Madsen, M | 1 |
Grove, EL | 2 |
Johnsen, SP | 2 |
Andersen, G | 2 |
Davidson, KW | 1 |
Burg, MM | 1 |
Carney, RM | 1 |
Freedland, KE | 1 |
Acikel, S | 1 |
Dogan, M | 1 |
Sari, M | 1 |
Kilic, H | 1 |
Akdemir, R | 1 |
Bah, TM | 1 |
Benderdour, M | 1 |
Kaloustian, S | 1 |
Karam, R | 1 |
Rousseau, G | 1 |
Godbout, R | 1 |
Labos, C | 1 |
Dasgupta, K | 1 |
Nedjar, H | 1 |
Turecki, G | 1 |
Rahme, E | 1 |
Jiang, W | 1 |
Velazquez, EJ | 1 |
Samad, Z | 1 |
Kuchibhatla, M | 1 |
Martsberger, C | 1 |
Rogers, J | 1 |
Williams, R | 1 |
Kuhn, C | 1 |
Ortel, TL | 1 |
Becker, RC | 1 |
Pristera, N | 1 |
Krishnan, R | 1 |
O'Connor, CM | 1 |
Zuidersma, M | 1 |
Conradi, HJ | 1 |
van Melle, JP | 3 |
Ormel, J | 3 |
de Jonge, P | 2 |
van den Brink, RH | 1 |
Honig, A | 2 |
Schene, AH | 2 |
Crijns, HJ | 1 |
Lambert, FP | 1 |
Pogosova, GV | 1 |
Zhidko, NI | 1 |
Mikheeva, TG | 1 |
Baĭchorov, IKh | 1 |
Sakkas, P | 1 |
Psarros, C | 1 |
Papadimitriou, GN | 1 |
Theleritis, CG | 1 |
Soldatos, CR | 1 |
Kuyper, AM | 1 |
Tulner, D | 1 |
Schins, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Efficacy and Safety of Escitalopram in the Treatment of Depressive Patients With Acute Coronary Artery Syndrome: A Double-blind Placebo-controlled Trial[NCT00419471] | Phase 4 | 300 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
The Efficacy of Citalopram Treatment in Acute Stroke[NCT01937182] | Phase 2 | 642 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463] | Phase 2 | 88 participants (Anticipated) | Interventional | 2021-07-18 | Recruiting | ||
Mindfulness-Based Cognitive Therapy Delivered Via Group Videoconferencing for Acute Coronary Syndrome Patients With Elevated Depression Symptoms[NCT03878160] | 27 participants (Actual) | Interventional | 2018-07-01 | Completed | |||
Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT Trial)[NCT00574847] | Phase 4 | 127 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
This is a 14-item scale that measures empathy. The scoring scale ranges from 0, does not describe me well, to 4, describes me very well. The score values range from 0-56, where high values represent higher levels of empathy and lower values represent lower levels of empathy. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) |
---|---|
Women and Men, <2 Years, Individual Interview | 41 |
Women and Men, >2 Years, Individual Interview | 39 |
Women and Men, Lifetime History of ACS, Individual Interview | 45 |
This is a 3-item scale that measures health behaviors. The scoring scale ranges from 1, none of the time, to 6, all of the time. The scoring values range from 3-18, where higher values represent good health behavior and lower values represent poor health behavior. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) |
---|---|
Women and Men, <2 Years, Individual Interview | 11 |
Women and Men, >2 Years, Individual Interview | 10 |
Women and Men, Lifetime History of ACS, Individual Interview | 13 |
This is a 9-item scale that measures depression. The scoring scale ranges from 0, not at all, to 3, nearly every day. The scoring values range from 0-18, where high values represent higher levels of depression and lower values represent lower levels of depression. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) |
---|---|
Women and Men, <2 Years, Individual Interview | 10.5 |
Women and Men, >2 Years, Individual Interview | 16 |
Women and Men, Lifetime History of ACS, Individual Interview | 1.5 |
This is a 4-item scale that measures and evaluates physical health. The scoring scale ranges from 5, without any difficulty, to 1, unable to do. The scoring values range from 4-20, where high values represent good physical function and low values represent poor physical function. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) |
---|---|
Women and Men, <2 Years, Individual Interview | 18 |
Women and Men, >2 Years, Individual Interview | 12 |
Women and Men, Lifetime History of ACS, Individual Interview | 20 |
This is a 4-item scale that measures stress. The scoring scale ranges from 0,never, to 4, very often. The scale values range from 0-16 with higher values representing higher levels of individual stress and lower values representing lower levels of individual stress. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) |
---|---|
Women and Men, <2 Years, Individual Interview | 12 |
Women and Men, >2 Years, Individual Interview | 14 |
Women and Men, Lifetime History of ACS, Individual Interview | 6 |
This is a 20-question scale, composed of 2, 10-item scales that measure positive and negative affect. The scoring scale ranges from 1, very slightly or not at all, to 5, extremely. For this study, we will only use the positive affect sub-scale. The scale values for the positive affect sub-scale range from 10-50. Higher values on the positive affect scale represent higher levels of positive affect, whereas, lower values on the negative affect scale represent lower levels of positive affect. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) |
---|---|
Women and Men, <2 Years, Individual Interview | 22 |
Women and Men, >2 Years, Individual Interview | 26 |
Women and Men, Lifetime History of ACS, Individual Interview | 34 |
This is a 22-item scale that measures rumination. The scoring scale ranges from 1,almost never, to 4, almost always. The score values range from 22 to 88, where higher values represent higher levels of rumination and lower values represent lower levels of rumination. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) |
---|---|
Women and Men, <2 Years, Individual Interview | 41 |
Women and Men, >2 Years, Individual Interview | 51.5 |
Women and Men, Lifetime History of ACS, Individual Interview | 31 |
This is a 16-item scale that measures views toward the self and others. This measure consists of four sub-scales with four items each. The sub-scales measure positive views toward self, negative views toward self, positive views toward others, and negative views toward other. Only the positive-other sub-scale was used. The scoring scale ranges from 1, very slightly or not at all to 5, extremely, with sub-scale scores ranging from 4-20. Higher values represent higher levels of positive feelings toward others, and lower values represent lower levels of positive feelings toward others. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) |
---|---|
Women and Men, <2 Years, Individual Interview | 15 |
Women and Men, >2 Years, Individual Interview | 12.5 |
Women and Men, Lifetime History of ACS, Individual Interview | 16 |
This is a 12-item scale that measures health-related quality of life. The scoring scale from item 1 ranges from 1, excellent to 5, poor. The scoring scale for items 2 and 3 ranges from 1, limit you a lot to 3, not limit you at all. The scoring scale for questions 5-7 is represented by 1, yes or 2, no. The scoring scale for item 8 ranges from 1, not at all, to 5, extremely. The scoring scale for items 9-11 ranges from 1, all of the time, to 6, none of the time. The scoring scale for item 12 ranges from 1, all of the time to 5, none of the time. The total scoring values range from 12- 47, where higher values represent a higher quality of life and lower values represent a lower quality of life. Data collection for this measurement is cross-sectional, and is performed during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) |
---|---|
Women and Men, <2 Years, Individual Interview | 26 |
Women and Men, >2 Years, Individual Interview | 22 |
Women and Men, Lifetime History of ACS, Individual Interview | 40 |
This is a 15-item measure that measures mindfulness. This scale has five sub-scales: observing, describing, acting with awareness, accepting without judgment, and non-reactivity. The scoring scale ranges from 1, never or very rarely true to 5, very often or always true. Scale values range from 3-15 for each sub-scale, with higher values representing greater levels of individual mindfulness and lower values representing lowers levels of individual mindfulness. There is no total score for the measure; only individual sub-scales are reported. Data collection for this measurement is cross-sectional, and is collected during one, 30-90 minute time interval. (NCT03878160)
Timeframe: 30-90-minute study session
Intervention | units on a scale (Median) | ||||
---|---|---|---|---|---|
Observing | Describing | Acting with awareness | Accepting without judgment | Nonreactivity | |
Women and Men, <2 Years, Individual Interview | 8 | 11 | 11 | 11 | 11 |
Women and Men, >2 Years, Individual Interview | 9 | 9 | 9 | 8 | 9.5 |
Women and Men, Lifetime History of ACS, Individual Interview | 10 | 13 | 10 | 14 | 14 |
This portion of the individual interview will focus on exploring changes experienced after an ACS, such as psychosocial changes and health behavior changes. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. The identified themes are reported, and the criteria used to determine the outcome measure is the number of participants who endorsed each theme. (NCT03878160)
Timeframe: one 30-90-minute session
Intervention | participants (Number) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Positive health behavior changes | Adaptive perspectives | Emotional improvements | Social improvements | Activity limitations | Negative physical symptoms | Emotional problems | Social problems | Health behavior challenges | |
Women and Men, <2 Years, Individual Interview | 3 | 1 | 0 | 1 | 5 | 5 | 3 | 3 | 2 |
Women and Men, >2 Years, Individual Interview | 3 | 0 | 1 | 0 | 7 | 8 | 8 | 2 | 5 |
Women and Men, Lifetime History of ACS, Individual Interview | 10 | 5 | 1 | 5 | 4 | 6 | 6 | 4 | 0 |
This portion of the individual interview will focus on exploring ACS patients who had perspectives on participating in a remote dried blood spot procedure. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. The criteria used to determine the outcome measure is the number of participants upon interview who reported any type of perspective on participating in a remote dried blood spot procedure (self-collection of dried blood spot via finger-prick). Please note that the number of perspectives reported for each theme can exceed the number of people per group because each participant reported multiple perspectives (e.g., both pros and cons of videoconferencing). (NCT03878160)
Timeframe: one 30-90-minute session
Intervention | participants (Number) | ||
---|---|---|---|
Willing to complete DBS | Would need training | Would want more information about the rationale | |
Women and Men, <2 Years, Individual Interview | 5 | 2 | 5 |
Women and Men, >2 Years, Individual Interview | 7 | 5 | 4 |
Women and Men, Lifetime History of ACS, Individual Interview | 8 | 2 | 6 |
This portion of the individual interview will focus on exploring patients' perspectives toward an MBCT treatment approach. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. The identified themes are reported, and the criteria used to determine the outcome measure is the number of participants who endorsed each theme. (NCT03878160)
Timeframe: one 30-90-minute session
Intervention | participants (Number) | ||
---|---|---|---|
Willing to get help | Willing to participate in a group program | Positive reaction to mindfulness | |
Women and Men, <2 Years, Individual Interview | 3 | 3 | 4 |
Women and Men, >2 Years, Individual Interview | 8 | 6 | 7 |
Women and Men, Lifetime History of ACS, Individual Interview | 8 | 8 | 7 |
This portion of the individual interview will focus on exploring perspectives regarding videoconferencing intervention delivery. Participants were individually interviewed via telephone using a semi-structured interview guide. Three independent coders conducted qualitative thematic analysis and results were analyzed within each group. Identified themes are reported, and the criteria used to determine the outcome measure is the number of participants upon interview who reported expressed each theme. (NCT03878160)
Timeframe: one 30-90-minute session
Intervention | participants (Number) | ||||
---|---|---|---|---|---|
Willing to try videoconferencing | Logistical benefits | Social benefits | Technology limitations | Social limitations | |
Women and Men, <2 Years, Individual Interview | 3 | 5 | 2 | 2 | 2 |
Women and Men, >2 Years, Individual Interview | 7 | 5 | 1 | 5 | 1 |
Women and Men, Lifetime History of ACS, Individual Interview | 8 | 7 | 1 | 2 | 4 |
End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: week 6
Intervention | fmol/mg (Mean) |
---|---|
Escitalopram | 139.7 |
Placebo | 160.4 |
The Beck Depression Inventory II (BDI-II) is a 21 question, self-administered measure of depressive symptoms. Score range, 0 to 63 (higher score=greater severity of depressive symptoms). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 week
Intervention | units on a scale (Mean) |
---|---|
Escitalopram | 7.4 |
Placebo | 7.0 |
hostile affect, 0 to 5 (higher score=greater levels of hostile affect). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
Intervention | units on a scale (Mean) |
---|---|
Escitalopram | 1.6 |
Placebo | 1.8 |
Score ranges: hostility, 0 to 27 (higher score=greater levels of hostility)/ End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
Intervention | units on a scale (Mean) |
---|---|
Escitalopram | 9.9 |
Placebo | 10.3 |
End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 week
Intervention | percentage of change (Number) |
---|---|
Escitalopram | 45.8 |
Placebo | 52.5 |
"A standard 12-lead Electrocardiograph (ECG) will be recorded at 1-minute intervals during the last 3 minutes of each rest period, the 3 minutes of the mental stress testing, and during exercise testing. Heart rate will be determined from the ECGs.~Mental Stress Induced Change in heart rate will be calculated by taking the mean of the mental stress heart rate measurements minus the resting heart rate measurements. End point values adjusted for baseline values age and sex." (NCT00574847)
Timeframe: baseline, 6 weeks
Intervention | beats/minute (Mean) |
---|---|
Escitalopram | 6.34 |
Placebo | 9.1 |
Blood pressure will be measured the last 3 minutes of the 20 minute calibration period (resting), every minute during the 3 minutes mental stress testing, the last 3 minutes of the 6 minute rest periods between mental stress testing, and every minute during and after the physical stress testing with an automatic oscillometric blood pressure monitor (Quinton Electronics). Mental Stress Induced Change of Diastolic Blood Pressure will be calculated by taking the mean of the mental stress Diastolic blood pressure measurements minus the resting Diastolic blood pressure. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: Baseline, week 6
Intervention | mm Hg (Mean) |
---|---|
Escitalopram | 11.4 |
Placebo | 12.2 |
Blood pressure will be measured the last 3 minutes of the 20 minute calibration period (resting), every minute during the 3 minutes mental stress testing, the last 3 minutes of the 6 minute rest periods between mental stress testing, and every minute during and after the physical stress testing with an automatic oscillometric blood pressure monitor (Quinton Electronics). Mental Stress Induced Change of Systolic Blood Pressure will be calculated by taking the mean of the mental stress systolic blood pressure measurements minus the resting Systolic blood pressure. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: Baseline, week 6
Intervention | mm Hg (Mean) |
---|---|
Escitalopram | 19.3 |
Placebo | 23.6 |
Score range, 10 to 50 (higher score = greater levels of perceived stress). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
Intervention | units on a scale (Mean) |
---|---|
Escitalopram | 21.4 |
Placebo | 21.8 |
(NCT00574847)
Timeframe: Baseline to week 6
Intervention | percentage of participants (Number) |
---|---|
Escitalopram | 71.9 |
Placebo | 44.4 |
MSIMI is defined by the following: compared to rest, 1) any development of new abnormal wall motion; 2) reduction of LVEF 8% and/or; 3) deviation (depression or elevation) of ST-segment of ECG in 2 or more leads lasting for 3 consecutive beats, occurring during at least one of the 3 mental stress tasks. (NCT00574847)
Timeframe: Week 6
Intervention | percentage of participants (Number) |
---|---|
Escitalopram | 34.2 |
Placebo | 17.5 |
MSIMI is defined by the following: compared to rest, 1) any development of new abnormal wall motion; 2) reduction of LVEF 8% and/or; 3) deviation (depression or elevation) of ST-segment of ECG in 2 or more leads lasting for 3 consecutive beats, occurring during at least one of the 3 mental stress tasks. (NCT00574847)
Timeframe: week 6
Intervention | percentage of participants (Number) |
---|---|
Escitalopram | 66.1 |
Placebo | 83.9 |
End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
Intervention | nM (Mean) |
---|---|
Escitalopram | 4202.4 |
Placebo | 210.1 |
STAI measures anxiety. The questionnaire asks the patients how they feel and allows them to respond on a frequency scale that ranges from 1(not at all) to 4(almost always/very much so). Scores range from 20-80 and the higher the score the greater the anxiety level. This applies to both the Trait and State scales. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
Intervention | units on a scale (Mean) | |
---|---|---|
Trait | State | |
Escitalopram | 31.2 | 27.9 |
Placebo | 32.0 | 29.5 |
1 review available for citalopram and Cardiovascular Stroke
Article | Year |
---|---|
Treatment-resistant depression and mortality after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Antidepressive Agents; Bupropion; Citalopram; Cognitive Behavioral Therapy; | 2009 |
8 trials available for citalopram and Cardiovascular Stroke
Article | Year |
---|---|
Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressi | 2018 |
Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Denmark; Double-Blind Method; Early Medi | 2018 |
Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Denmark; Double-Blind Method; Early Medi | 2018 |
Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Denmark; Double-Blind Method; Early Medi | 2018 |
Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS).
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Citalopram; Denmark; Double-Blind Method; Early Medi | 2018 |
TALOS: a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke.
Topics: Brain Ischemia; Citalopram; Double-Blind Method; Follow-Up Studies; Humans; Mental Status Schedule; | 2015 |
Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial.
Topics: Adult; Cardiovascular Diseases; Citalopram; Depressive Disorder; Exercise Test; Humans; Myocardial I | 2012 |
Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial.
Topics: Aged; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Fo | 2013 |
Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT).
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Double-Blind Method; Follow-Up Studie | 2002 |
[Clinical effectiveness and safety of citalopram in patients with depression after myocardial infarction].
Topics: Adult; Aged; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Dis | 2003 |
Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events.
Topics: Antidepressive Agents; Cardiovascular Diseases; Cause of Death; Citalopram; Comorbidity; Depressive | 2007 |
5 other studies available for citalopram and Cardiovascular Stroke
Article | Year |
---|---|
Implementing an antidepressant treatment strategy for post-MI depression does not reduce risk of further cardiovascular events or mortality.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder, Major; Female; Humans; Male; Mianserin; Myoc | 2013 |
Prinzmetal-variant angina in a patient using zolmitriptan and citalopram.
Topics: Angina Pectoris, Variant; Citalopram; Coronary Angiography; Coronary Vasospasm; Drug Therapy, Combin | 2010 |
Escitalopram reduces circulating pro-inflammatory cytokines and improves depressive behavior without affecting sleep in a rat model of post-cardiac infarct depression.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Citalopram; Cytokines; Depr | 2011 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Ag | 2011 |
Repetitive transcranial magnetic stimulation (rTMS) in a patient suffering from comorbid depression and panic disorder following a myocardial infarction.
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Citalopram; Clorazepate Dipotassium; | 2006 |